In recent years, GLP-1 medications have gained a lot of traction. They not only help in managing Type 2 diabetes; they also play a major role in helping people lose weight. But now, recent research suggests that these medications may help in protecting the brain from cognitive decline, too.
Two newly published observational studies have found that people taking GLP-1 medications had a lower risk of developing dementia, including Alzheimer’s disease and related cognitive disorders. These findings, although early, spark new hope among weight loss doctors and patients alike.
Let’s see what these studies found and what it means for the future of dementia prevention.
What Are GLP-1 Medications for Weight Loss?
GLP-1s are a class of medications that were originally developed to treat Type 2 diabetes. They work by mimicking the role of the GLP-1 hormone in the body, which helps to regulate blood sugar levels, suppress appetite, and slow digestion. Popular GLP-1 weight loss medications include Semaglutide (sold under the names Ozempic and Wegovy), Liraglutide (Saxenda), and others.
More recently, these medications have gained attention for their effectiveness in protecting brain health.
The New Studies: A Closer Look
1. Meta-Analysis of 26 Randomized Trials
A group of researchers and medical students at the University of Galway in Ireland conducted 26 randomized clinical trials to evaluate the role of GLP-1 Ras and other diabetes drugs in reducing the risk of dementia and cognitive impairment.
They found a significant reduction (45% lower chance) in the risk of developing dementia among people who took GLP-1 medications.
2. Electronic Health Record Review
The second study analyzed over 100,000 real-world patient records from a large health database. This study also showed that the people who started GLP-1 treatment had about 33% lower risk of dementia than those who didn’t take these drugs.
How GLP-1 Weight Loss Medications Benefit the Brain?
While the exact mechanism of how GLP-1 weight loss medications benefit the brain is not entirely clear, researchers do have some theories:
- Reduces Inflammation: GLP-1s may reduce chronic inflammation, which plays a role in both diabetes and neurodegenerative diseases.
- Improves Blood Flow: By improving heart health, GLP 1 weight loss drugs may enhance the flow of blood to the brain.
- Provides Weight and Metabolic Control: Obesity, insulin resistance, and high blood sugar are known risk factors for dementia. By controlling these, these weight loss drugs may indirectly protect brain health.
- Neuroprotective Action: Some studies suggest GLP-1 medications for weight loss may act directly on the brain to protect neurons and improve function.
Should You Start Taking a GLP-1 Drug for Brain Health?
Not just yet.
Large-scale, randomized controlled EVOKE and EVOKE+ trials are still underway, both looking at the impact of Semaglutide on mild cognitive impairment (MCI). These studies aim to measure whether the drug can slow the progression to Alzheimer’s disease.
The results are expected by the end of 2025, and if they confirm what the observational studies are suggesting, it could open up a whole new use case for GLP-1 medications in neurology.
While the idea is promising, GLP-1 medications:
- They aren’t approved for dementia prevention or treatment,
- May have side effects (like nausea, gastrointestinal issues, and in rare cases, pancreatitis), and
- Are expensive, especially if not covered by insurance.
If you’re already prescribed GLP-1 medicines for weight loss and diabetes, the potential brain benefit may be an added bonus. But starting one just for dementia prevention is not recommended, at least until more research confirms the effect.
As always, speak with a board-certified obesity medicine physician like Dr. Mona Lala before considering GLP-1 for weight loss or diabetes.
Schedule an appointment today for a personalized consultation and find out if GLP-1 medications could be right for you or your loved one.
